These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Genetics of the immune response]. Tsoneva M Vutr Boles; 1983; 22(5):1-13. PubMed ID: 6424336 [No Abstract] [Full Text] [Related]
3. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585 [TBL] [Abstract][Full Text] [Related]
4. [Antigenic signal to immunocompetent cells]. Marx A Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1985; 30(1):1-12. PubMed ID: 3159067 [No Abstract] [Full Text] [Related]
5. Mhc restriction and Ir genes. Klein J; Nagy ZA Adv Cancer Res; 1982; 37():233-317. PubMed ID: 6222631 [No Abstract] [Full Text] [Related]
6. The cellular and humoral basis of the immune response. Yunis E Semin Arthritis Rheum; 1983 Aug; 13(1 Suppl 1):89-93. PubMed ID: 6414085 [TBL] [Abstract][Full Text] [Related]
7. HLA and cancer. Garrido F Tissue Antigens; 1996 May; 47(5):361-3. PubMed ID: 8795135 [No Abstract] [Full Text] [Related]
8. An introduction to tumour immunology. Keith J Mater Med Pol; 1984; 16(1):54-64. PubMed ID: 6394909 [No Abstract] [Full Text] [Related]
9. Immunological help at last. Howard JC Nature; 1985 Apr 11-17; 314(6011):494-5. PubMed ID: 3157868 [No Abstract] [Full Text] [Related]
10. Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejection. Ostrand-Rosenberg S; Garcia EP; Roby CA; Clements VK Semin Cancer Biol; 1991 Oct; 2(5):311-9. PubMed ID: 1773047 [TBL] [Abstract][Full Text] [Related]
11. [The immune system - how does anti-tumor immunity arise ?]. Sankawa Y Oncol Res Treat; 2014; 37 Suppl 4():2-5. PubMed ID: 25301189 [No Abstract] [Full Text] [Related]
12. Experiments and speculation on antiviral specificity of T and B cells. Zinkernagel RM; Rosenthal KL Immunol Rev; 1981; 58():131-55. PubMed ID: 6171502 [No Abstract] [Full Text] [Related]
13. Immune response to autologous human melanoma: implication of class I and II MHC products. Fossati G; Anichini A; Taramelli D; Balsari A; Gambacorti-Passerini C; Kirkwood JM; Parmiani G Biochim Biophys Acta; 1986 Dec; 865(3):235-51. PubMed ID: 3539196 [No Abstract] [Full Text] [Related]
15. MHC class I restricted T cells and immune surveillance against transplanted ultraviolet light-induced tumors. Ward PL; Schreiber H Semin Cancer Biol; 1991 Oct; 2(5):321-8. PubMed ID: 1837738 [TBL] [Abstract][Full Text] [Related]
16. Cell-mediated immune reactions to human tumors. Perlmann P; Troye M; Pape GR Cancer; 1977 Jul; 40(1 Suppl):448-57. PubMed ID: 69485 [No Abstract] [Full Text] [Related]
18. The suppressor-cell network in cancer (first of two parts). Broder S; Waldmann TA N Engl J Med; 1978 Dec; 299(23):1281-4. PubMed ID: 101844 [No Abstract] [Full Text] [Related]
19. [Mechanism of immune response]. Gülmezoğlu E Mikrobiyol Bul; 1982 Jul; 16(3):217-23. PubMed ID: 6820118 [TBL] [Abstract][Full Text] [Related]
20. The immunology of ageing. Ford PM Clin Rheum Dis; 1986 Apr; 12(1):1-10. PubMed ID: 3522079 [No Abstract] [Full Text] [Related] [Next] [New Search]